Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15,512 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A preoperative low cancer antigen 125 level (≤25.8 mg/dl) is a useful criterion to determine the optimal timing of interval debulking surgery following neoadjuvant chemotherapy in epithelial ovarian cancer.
Morimoto A, Nagao S, Kogiku A, Yamamoto K, Miwa M, Wakahashi S, Ichida K, Sudo T, Yamaguchi S, Fujiwara K. Morimoto A, et al. Among authors: yamamoto k. Jpn J Clin Oncol. 2016 Jun;46(6):517-21. doi: 10.1093/jjco/hyw029. Epub 2016 Mar 13. Jpn J Clin Oncol. 2016. PMID: 26977055
Dose-dense paclitaxel and carboplatin vs. conventional paclitaxel and carboplatin as neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: a retrospective study.
Shibutani T, Nagao S, Suzuki K, Kaneda M, Yamamoto K, Jimi T, Yano H, Kitai M, Shiozaki T, Matsuoka K, Sudo T, Yamaguchi S. Shibutani T, et al. Among authors: yamamoto k. Int J Clin Oncol. 2020 Mar;25(3):502-507. doi: 10.1007/s10147-019-01567-y. Epub 2019 Nov 1. Int J Clin Oncol. 2020. PMID: 31677021
A phase II study of the combination chemotherapy of bevacizumab and gemcitabine in women with platinum-resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
Nagao S, Kogiku A, Suzuki K, Shibutani T, Yamamoto K, Jimi T, Kitai M, Shiozaki T, Matsuoka K, Yamaguchi S. Nagao S, et al. Among authors: yamamoto k. J Ovarian Res. 2020 Feb 7;13(1):14. doi: 10.1186/s13048-020-0617-y. J Ovarian Res. 2020. PMID: 32028974 Free PMC article. Clinical Trial.
Phase II study of a new multidisciplinary therapy using once every 3 week carboplatin plus dose-dense weekly paclitaxel before and after radical hysterectomy for locally advanced cervical cancer.
Nagao S, Yamamoto K, Oishi T, Yamaguchi S, Takehara K, Shimada M, Kigawa J. Nagao S, et al. Among authors: yamamoto k. Int J Clin Oncol. 2021 Jan;26(1):207-215. doi: 10.1007/s10147-020-01787-7. Epub 2020 Sep 22. Int J Clin Oncol. 2021. PMID: 32960420 Clinical Trial.
Quality of life assessment of cell-free and concentrated ascites reinfusion therapy during initial treatment for advanced ovarian cancer: A prospective cohort study.
Yamamoto K, Nagao S, Tsu T, Matsushima T, Ishido Y, Narita M, Suzuki K, Nakazawa H, Shibutani T, Jimi T, Yano H, Kitai M, Shiozaki T, Matsuoka K, Yamaguchi S. Yamamoto K, et al. J Obstet Gynaecol Res. 2021 Apr;47(4):1536-1543. doi: 10.1111/jog.14670. Epub 2021 Jan 20. J Obstet Gynaecol Res. 2021. PMID: 33469981
15,512 results
You have reached the last available page of results. Please see the User Guide for more information.